日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Global cancer statistics for children: Two decades of change and projections to 2050

全球儿童癌症统计数据:二十年来的变化及至2050年的预测

Li, Wangzhong; Huang, Shanzhou; Chen, Qiyue; Wang, Ting; Lu, Guanming; Niu, Xing; Song, Qiong; Xu, Yilin; Mo, Ke; Cui, Chunhui; Zhang, Run; Du, Wei; He, Feiying; Shi, Lei; Lin, Yan; Wei, Qiu; Jiang, Li; Chen, Yongsheng; Song, Baiyang; Zhang, Huijuan; Fu, Zhenli; Liao, Wenjing; Sun, Jiancong; Guan, Wenhui; Zhuang, Weitao; Zhong, Nanshan; Zhou, Chengzhi; Liang, Wenhua; Kang, Min; He, Jianxing

Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial

一项多中心、随机、双盲、安慰剂对照的3期临床试验:在初诊晚期卵巢癌患者中,使用氟哌啶醇联合或不联合阿帕替尼作为维持治疗方案的疗效评价(FZOCUS-1):一项多中心、随机、双盲、安慰剂对照试验

Wu, Lingying; Wang, Jing; Li, Qingshui; Wang, Danbo; Zhang, Cuiying; Tang, Junying; Zhang, Guonan; Hao, Min; Yao, Desheng; Gao, Qinglei; Zhang, Youzhong; An, Ruifang; Yin, Rutie; Wang, Li; Xia, Bairong; Zhou, Qi; Yang, Hongying; Zhu, Jianqing; Jiang, Kui; Chen, Zhengzheng; Wu, Qiang; Duan, Wei; Huang, Yi; Zhang, Hui; Wei, Shuqing; Li, Guiling; Meng, Yuanguang; Wang, Ke; Yang, Xinfeng; Huang, Xianghua; Pan, Lingya; Yu, Jinjin; Lou, Ge; Zhang, Yu; Zhou, Huaijun; Guo, Xiaoqing; Yang, Hong; Cheng, Xiaodong; Li, Xiumin; Wang, Wuliang; Zhao, Hongqin; Li, Yunxia; Yang, Yingjie; Lin, An; Cheng, Wenjun; Chen, Lihong; Xie, Xiaoying; Di, Wen; Hu, Yuanjing; Chen, Mo; Wen, Hongwu; Cai, Liping; Wu, Xiaohua; Lin, Zhongqiu; Wang, Quanren; Yang, Xinfeng; Li, Ning

Anti-PD-1 antibody penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: a randomized, double-blind phase 3 study

抗PD-1抗体penpulimab联合化疗治疗复发性或转移性鼻咽癌:一项随机、双盲3期研究

Huang, Shuang; Liu, Feng; Qu, Song; Chen, Lisha; Zhou, Ping; Qu, Shenhong; Ai, Xiaohong; Chen, Yong; Liu, Meilian; Wang, Rensheng; Chan, Kelvin Kw; Zhang, Peng; Hu, Chunhong; Wen, Jiyu; Zhang, Jian; Lin, Qin; Li, Xiaojiang; Gu, Kangsheng; Xiang, Li; Wang, Dongxia; Li, Jingao; Lin, Daren; Hu, Desheng; Ding, Jianwu; Wang, Siyang; Huang, Xiaoming; Wang, Lin; Jin, Feng; Pfister, David G; Mak, Milena Perez; Marchi, Pedro Rafael Martins de; Jiang, Yi; Yang, Haihua; Hu, Xiaoye; Liu, Tianrun; Wu, Dehua; Shreenivas, Aditya; Oliveira, Thiago Bueno de; Silva, Carlos Eduardo Baston; Alves, Gustavo Vasconcelos; Li, Xianming; Yao, Zhifang; Lu, Dongmei; Hu, Mingxiu; Wang, Zhongmin Maxwell; Li, Baiyong; Xia, Michelle; Chen, Xiaozhong; Hu, Chaosu; Xu, Tingting

Deutenzalutamide, a novel androgen receptor inhibitor, after progression on docetaxel and abiraterone in metastatic castration-resistant prostate cancer: results from the randomized phase III HC-1119-04 trial

在转移性去势抵抗性前列腺癌患者接受多西他赛和阿比特龙治疗后出现疾病进展的情况下,新型雄激素受体抑制剂氘代沙鲁胺的疗效:来自随机 III 期 HC-1119-04 试验的结果

Wu, Junlong; Li, Xinghai; Gu, Chengyuan; Hua, Lixin; Liu, Ranlu; Li, Jun; Qiu, Mingxing; Guo, Jianming; Dong, Haiying; Ji, Zhigang; Xie, Liping; Zhu, Shaoxing; Zhang, Xuhui; Chen, Peng; Jiang, Shusuan; Sun, Zhongquan; Xu, Danfeng; Chen, Hui; Shi, Benkang; Wang, Yujie; Pu, Jinxian; Perabo, Frank; Chen, Yuanwei; Ye, Dingwei

HDAC inhibitor tucidinostat and metronomic capecitabine plus endocrine therapy for patients with HR-positive HER2-negative advanced breast cancer after CDK4/6 inhibitors treatment: clinical findings and exploratory circulating tumor cell and ctDNA biomarker analyses of a multicenter, phase 2 study (SYSUCC-020 trial)

HDAC抑制剂tucidinostat和节拍式卡培他滨联合内分泌治疗用于CDK4/6抑制剂治疗后HR阳性HER2阴性晚期乳腺癌患者:一项多中心2期研究的临床结果和探索性循环肿瘤细胞和ctDNA生物标志物分析(SYSUCC-020试验)

Wu, Huai-Liang; Xia, Wen; Xu, Zhengyang; Zhou, Hanxing; Chen, Limin; Lu, Yongkui; Liu, Xinlan; Pang, Danmei; Liu, Yan; Lu, Qianyi; Xu, Fei; An, Xin; Huang, Jiajia; Jiang, Kuikui; Zhang, Jingmin; Cai, Yili; Hong, Ruoxi; Zheng, Qiufan; Wang, Shusen

RMzyme: regulations of RNA-modifying enzymes in humans.

RMzyme:人类RNA修饰酶的调控。

Luo Ruihan, Xu Haixia, Zhou Qingbo, Ding Shanli, Qiang Min, Wen Jianguo, Kim Pora, Yang Xiaojuan, Cai Yunshi, Xie Kunlin, Zhu Jiang, Xu Yungang, Lan Tian, Zhou Xiaobo, Wu Hong

Extraocular delivery of bioswitchable tri-miR-22-loaded tetrahedral DNA nanostructures for intraocular neovascular and neurodegenerative repair.

将载有生物可切换三 miR-22 的四面体 DNA 纳米结构进行眼外递送,用于眼内新生血管和神经退行性病变的修复。

Wang Qiong, Wang You, Chen Li, Huang Junyang, Cai Tao, Lin Yi, Liu Jingying, Liu Jinnan, Zhu Jiang, Li Rong, Luo Delun, Ding Xiaoyan

Factor IX-Padua AAV gene therapy in hemophilia B: phases 1/2 and 3 trials

IX因子-Padua AAV基因疗法治疗B型血友病:1/2期和3期试验

Xue, Feng; Ju, Mankai; Zhu, Tienan; Zhou, Zeping; Sun, Jing; Yang, Linhua; Yan, Zhenyu; Zhou, Hu; Du, Xin; Zheng, ChangCheng; Zheng, Jing; Wu, Xia; Du, Zengmin; Jiang, Wei; Yang, Caifeng; Xiao, Xiao; Liu, Wei; Yang, Renchi; Zhang, Lei

Targeting of HIF2-driven cachexia in kidney cancer.

针对肾癌中由HIF2驱动的恶病质的靶向治疗。

Abu-Remaileh Muhannad, Stransky Laura A, Bhalerao Nikita, Shirole Nitin H, Jiang Qinqin, Saad Eddy, Machaalani Marc, Vigeant Sean M, Woldemichael Hilina, Xu Charles, Lu Jing, Wei Hairong, Liu Zhihong, Sun William, Enomoto Kei, Choueiri Toni K, Pitarresi Jason R, Carr Steven A, Udeshi Namrata D, Kaelin William G Jr

Phenome-wide analysis of copy number variants in 470,727 UK Biobank genomes

对英国生物银行470,727个基因组中的拷贝数变异进行全表型组分析

Zou, Xueqing Zoe; Hu, Fengyuan; Lou, Haiyi; Burren, Oliver S; Li, Xiaoyin; Megy, Karyn; Wheeler, Eleanor; Wu, Qiang; Atanur, Santosh S; Karpinski, Marcin; Loesch, Douglas; Fairhurst-Hunter, Zammy; Deevi, Sri V V; Oerton, Erin; Wen, Sean; Jiang, Xiao; Salvoro, Cecilia; Mitchell, Jonathan; Nag, Abhishek; Hollis, Ben; O'Neill, Amanda; Harrow, Jen; MacArthur, Stewart; Wasilewski, Sebastian; O'Dell, Sean; Tian, Lifeng; Smith, Katherine R; Del Angel, Guillermo; Fabre, Margarete; Dhindsa, Ryan S; Wang, Quanli; Petrovski, Slavé; Carss, Keren